iCamumo

What iCamumo does

iCamumo (艾凯利元生物科技有限公司 / iCamuno Biotherapeutics) is a private, clinical-stage Chinese biotechnology company founded in March 2021 and headquartered in Suzhou, with additional research operations in Hangzhou and Melbourne. The company develops off-the-shelf, universal cell therapy pharmaceuticals derived from induced pluripotent stem cells (iPSCs), targeting oncology (solid tumors, B-cell malignancies, multiple myeloma) and chronic degenerative diseases (Parkinson's disease, osteoarthritis, ophthalmology, ALS disease models).

The company's scientific foundation is its proprietary TNT (Transient Naive Treatment) reprogramming technology, developed by founder Liu Xiaodong and published in Nature, which eliminates epigenetic memory and aberrations from iPSCs to produce 'super iPSCs' (iCam-iPSC) that are molecularly and functionally closer to embryonic stem cells. This sits inside three integrated platforms — iCam-iPSC Super Stem Cell, iCam-Intelligent Engineering (gene editing), and iCam-Algorithm-Guided Expansion and Differentiation (AI plus single-cell multi-omics) — anchored by a GMP-grade three-tier iPSC cell bank. The disclosed pipeline comprises seven candidates (ICA01, ICA01TB, ICA2001, ICA3001 in oncology; ICA03, ICA06, ICA07 in regenerative indications), with ICA01 in investigator-initiated clinical trials for solid tumors and ICA03 in clinical preparation in Australia.

iCamumo operates a platform-plus-product business model with no commercial revenue to date. Revenue is expected to derive from off-the-shelf cell therapy product sales upon regulatory approval and from licensing/royalty arrangements for its TNT and differentiation technologies. The company has raised over USD 55M cumulatively from investors including Westlake Innovation Investment, 5Y Capital, Lianxin Capital, Kaywind Ventures, InnoVision Capital, Deren Capital, ByteDance, and Kingson Pharma, with a RMB 100M+ A++ round closed in August 2023. Go-to-market relies on IIT-style clinical collaborations with leading hospitals (Zhejiang University Second Affiliated Hospital), international research partnerships (University of Western Australia, Monash University, University of Adelaide), and patient-platform alliances (Cai Lei / Jianyu Huzhu Zhijia for ALS), with all pipeline products carrying global rights.

Name

iCamumo

Legal name

艾凯利元生物科技有限公司

Website

https://icamunobio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Short description

iCamumo is a Suzhou-based clinical-stage biotech founded in 2021 that develops off-the-shelf, iPSC-derived cell therapy pharmaceuticals for oncology and chronic degenerative diseases using its proprietary TNT reprogramming platform, with pipeline candidates in IIT and preclinical stages and global rights across all assets.

Ownership category

akta.pro rank

Product category

Cell Therapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• IPSC cell therapy
• Regenerative medicine
• Tumor immunotherapy
• Stem cell reprogramming
• Off-the-shelf cell drugs

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Cell Therapy Product Sales: The company develops and commercializes off-the-shelf (universal) cell therapy drugs derived from iPSCs for oncology (solid tumors, B-cell malignancies, multiple myeloma) and chronic degenerative diseases (Parkinson's, osteoarthritis, ophthalmology). Revenue is expected to come from product sales upon regulatory approval.
2. Licensing and Technology Transfer: iCamumo licenses its proprietary TNT reprogramming technology, iCam-iPSC platform, and differentiation technologies to pharmaceutical and biotech partners for drug discovery, disease modeling, and cell therapy development.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

iCamumo develops off-the-shelf, universal cell therapy pharmaceuticals derived from induced pluripotent stem cells (iPSCs) for oncology (solid tumors, B-cell malignancies, multiple myeloma) and chronic degenerative diseases (Parkinson's disease, osteoarthritis, ophthalmology). The company leverages its proprietary TNT reprogramming technology and three integrated platforms (iCam-iPSC, iCam-Intelligent Engineering, iCam-Algorithm-Guided Expansion and Differentiation) to produce clinical-grade super-iPSCs and differentiated therapeutic cell products, with planned licensing and product sales revenue streams.

Product overview

iCamumo is a biotech company developing off-the-shelf, effective, and affordable iPSC-based cell therapy drugs. The company operates a platform-plus-products model built on three proprietary technology platforms: the iCam-iPSC Super Stem Cell Platform (using TNT reprogramming for 'super iPSCs'), the iCam-Intelligent Engineering Platform (for gene editing), and the iCam-Algorithm-Guided Expansion and Differentiation Platform (using AI and single-cell multi-omics for cell differentiation). The therapeutic portfolio includes oncology products (ICA01 for solid tumors, ICA01TB for B-cell malignancies, ICA2001 for multiple myeloma, ICA3001 for multi-cancer) and chronic degenerative disease products (ICA03 for osteoarthritis, ICA06 for ophthalmology, ICA07 for Parkinson's disease).

Differentiator

Problem solved

Functional benefit

Products and services

• ICA01

Quantifiable outcome

• TNT reprogramming corrects epigenetic memory and aberrations, producing iPSCs molecularly and functionally closer to ESCs than conventional iPSCs
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Three partnerships are on record, tiered major and core.

• University of Western Australia (西澳大学), Monash University (莫纳什大学), University of Adelaide (阿德莱德大学)majorStrategic or Co-development Partner · 1 December 2024International team collaboration for NHMRC-funded project「新型重编程技术开发及应用」(Novel Reprogramming Technology Development and Application). Aims to advance TNT reprogramming technology toward clinical application in cell therapy and regenerative medicine. Prof. Matthew McCormack serves as Senior R&D Director at iCamumo leading this collaboration.
• Cai Lei / Jianyu Huzhu Zhijia (蔡磊 / 渐愈互助之家)coreStrategic or Co-development Partner · 15 July 2024Joint laboratory establishment for ALS (渐冻症) stem cell disease model and drug screening. iCamumo collaborates with Cai Lei (former JD.com VP and ALS fighter) and his Jianyu Huzhu Zhijia platform (linking thousands of ALS patients) to use iPSC-derived motor neurons and neuromuscular organoids for disease research, drug screening, and evaluation. A mutual strategic partnership combining iCamumo's iPSC technology with the patient's live data platform for ALS research acceleration.
• Zhejiang University School of Medicine Affiliated Second Hospital (浙江大学医学院附属第二医院)coreStrategic or Co-development Partner · 11 April 2024Clinical research collaboration on hiPSC-derived neural cell therapy for Parkinson's disease. Led by Prof. Zhang Baorong (神经内科), with participation of Prof. Yan Feng (功能神经外科) and Prof. Pu Jiali. Combines iCamumo's reprogramming and stem cell differentiation technology with the hospital's neurological clinical expertise. First clinical research collaboration for iCamumo's neural cell therapy pipeline.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Fate Therapeutics: Fate Therapeutics is the global leader in off-the-shelf iPSC-derived NK and T cell therapies for oncology, using a comparable platform-plus-products model targeting solid tumors, B-cell malignancies, and multiple myeloma. Closest direct competitor to iCamumo's oncology pipeline (ICA01/ICA01TB/ICA2001/ICA3001).
• Nkarta Therapeutics: Nkarta Therapeutics develops allogeneic off-the-shelf NK cell therapies for hematologic malignancies and solid tumors. Shares iCamumo's positioning around universal cell therapy as a lower-cost alternative to autologous CAR-T.
• Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic NK and T cell therapies with gene editing for oncology, sharing iCamumo's iPSC-platform-plus-multiplexed-product strategy. Most comparable peer in terms of modality, manufacturing approach, and target indications.
• Shoreline Biosciences: Shoreline Biosciences develops iPSC-derived NK cell immunotherapies for oncology and has multiple Big Pharma partnerships. Comparable to iCamumo's NK-focused solid tumor program with off-the-shelf iPSC platform.
• CellOrigin Biotech: CellOrigin Biotech is a Chinese iPSC-derived cell therapy company developing off-the-shelf CAR-NK and macrophage products for oncology. Closest direct China-based competitor to iCamumo's iPSC NK/T cell pipeline.

Broad incumbents

• Allogene Therapeutics: Allogene is the leading allogeneic CAR-T developer with a broader pipeline of off-the-shelf engineered T cell therapies. Larger and more clinically advanced than iCamumo but operates in the same off-the-shelf cell therapy paradigm for oncology.
• Cellectis: Cellectis is a clinical-stage gene-editing cell therapy company developing allogeneic CAR-T and NK cell platforms using TALEN gene editing. Comparable enabling technology stack to iCamumo's iCam-Intelligent Engineering gene-editing platform.

Emerging players

• Caribou Biosciences: Caribou Biosciences develops allogeneic CAR-NK and CAR-T cell therapies using CRISPR gene editing, with oncology focus. Comparable platform technology approach to iCamumo's gene-edited iPSC-derived immune cells.
• Cytovia Therapeutics: Cytovia develops iPSC-derived NK cells and gene-edited cell therapies for solid tumors and hematologic malignancies. Earlier-stage emerging player with comparable iPSC-NK focus.

Regional players

• JW Therapeutics: JW Therapeutics is a leading China-based cell therapy company commercializing autologous CAR-T products (Carteyva) and expanding into allogeneic formats. Most relevant Chinese peer for understanding local cell therapy commercial dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/icamuno-biotherapeutics-pty-ltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iCamumo